Athersys, Inc. announced today that the Medicines and Healthcare products Regulatory Agency has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStemA therapy to patients who have suffered an ischemic stroke.
http://www.pressreleasepoint.com/athersys-announces-authorization-stem-cell-clinical-trial-stroke-united-kingdom
http://www.pressreleasepoint.com/athersys-announces-authorization-stem-cell-clinical-trial-stroke-united-kingdom
No comments:
Post a Comment